VIATRIS INC. Total Liabilities
VIATRIS INC. (VTRS) had Total Liabilities of $20.78 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-06
- 2026-06-30: Liabilities $20.78B.
- 2026-03-31: Liabilities $22.18B.
- 2025-12-31: Liabilities $22.48B.
- 2025-09-30: Liabilities $22.70B.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $20.78B 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $22.18B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $22.48B 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $22.70B 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $22.84B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $22.82B 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $22.87B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $24.96B 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $25.81B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $27.33B 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $27.22B 10-K · filed 2025-02-27 | |
| 2023-09-30 | $27.88B 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $27.85B 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $28.36B 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $28.95B 10-K · filed 2024-02-28 | |
| 2022-09-30 | $29.48B 10-Q · filed 2022-11-07 | |
| 2022-06-30 | $31.32B 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $33.02B 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $34.35B 10-K · filed 2023-02-27 | |
| 2021-09-30 | $34.93B 10-Q · filed 2021-11-08 | |
| 2021-06-30 | $36.78B 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $37.56B 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $38.60B 10-K · filed 2022-02-28 | |
| 2020-09-27 | $11.61B 10-Q · filed 2020-11-10 | |
| 2020-06-28 | $11.41B 10-Q · filed 2020-08-12 | |
| 2020-03-29 | $0.00 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $19.37B 10-K · filed 2021-03-01 | $0.00 10-K · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |